News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
680,677 Results
Type
Article (56442)
Company Profile (163)
Press Release (624060)
Multimedia
Podcasts (183)
Webinars (23)
Section
Business (179455)
Career Advice (2539)
Deals (32950)
Drug Delivery (167)
Drug Development (77462)
Employer Resources (168)
FDA (17573)
Job Trends (14415)
News (317228)
Policy (34101)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2748)
Academic (1)
Accelerated approval (56)
ADA (47)
Adcomms (40)
Allergies (185)
Alliances (45014)
ALS (225)
Alzheimer's disease (1902)
Antibody-drug conjugate (ADC) (522)
Approvals (17898)
Artificial intelligence (745)
ASCO (333)
Autoimmune disease (338)
Automation (52)
Bankruptcy (344)
Best Places to Work (10902)
BIOSECURE Act (23)
Biosimilars (240)
Biotechnology (99)
Bladder cancer (207)
Brain cancer (78)
Breast cancer (784)
Cancer (6219)
Cardiovascular disease (533)
Career advice (2168)
Career pathing (49)
CAR-T (344)
CDC (76)
Celiac Disease (3)
Cell therapy (955)
Cervical cancer (54)
Clinical research (67910)
Collaboration (2091)
Company closure (7)
Compensation (1464)
Complete response letters (105)
COVID-19 (2911)
CRISPR (115)
C-suite (1190)
Cystic fibrosis (162)
Data (8316)
Decentralized trials (3)
Denatured (53)
Depression (188)
Dermatology (95)
Diabetes (657)
Diagnostics (6652)
Digital health (59)
Diversity (11)
Diversity, equity & inclusion (43)
Drug discovery (330)
Drug pricing (240)
Drug shortages (36)
Duchenne muscular dystrophy (309)
Earnings (74743)
Editorial (78)
Employer branding (20)
Employer resources (149)
Events (103295)
Executive appointments (1121)
FDA (21545)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (19)
Frontotemporal dementia (34)
Funding (1746)
Gene editing (248)
Generative AI (67)
Gene therapy (771)
GLP-1 (1228)
Government (4867)
Grass and pollen (8)
Guidances (413)
Healthcare (18776)
Hematology (187)
HIV (88)
Huntington's disease (62)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (115)
Immunology and inflammation (342)
Immuno-oncology (103)
Indications (197)
Infectious disease (3277)
Inflammatory bowel disease (226)
Inflation Reduction Act (15)
Influenza (132)
Intellectual property (302)
Interviews (464)
IPO (15606)
IRA (58)
Job creations (3804)
Job search strategy (1769)
JPM (70)
Kidney cancer (22)
Labor market (107)
Layoffs (661)
Leadership (52)
Legal (8059)
Liver cancer (109)
Longevity (29)
Lung cancer (845)
Lymphoma (452)
Machine learning (60)
Management (57)
Manufacturing (1082)
MASH (219)
Medical device (14753)
Medtech (14900)
Mergers & acquisitions (18601)
Metabolic disorders (1741)
mRNA (246)
Multiple sclerosis (186)
NASH (24)
Neurodegenerative disease (472)
Neuropsychiatric disorders (123)
Neuroscience (3536)
Neurotech (2)
NextGen: Class of 2026 (6301)
Non-profit (4276)
Now hiring (58)
Obesity (845)
Opinion (320)
Ovarian cancer (223)
Pain (275)
Pancreatic cancer (333)
Parkinson's disease (391)
Partnered (31)
Patents (616)
Patient recruitment (738)
Peanut (64)
People (56698)
Pharmaceutical (44)
Pharmacy benefit managers (37)
Phase 1 (20649)
Phase 2 (29662)
Phase 3 (23115)
Pipeline (9322)
Policy (388)
Postmarket research (2652)
Preclinical (8398)
Press Release (39)
Prostate cancer (339)
Psychedelics (66)
Radiopharmaceuticals (338)
Rare diseases (1224)
Real estate (5527)
Recruiting (68)
Regulatory (27111)
Reports (48)
Research institute (2513)
Resumes & cover letters (418)
Rett syndrome (41)
RNA editing (26)
RSV (92)
Schizophrenia (193)
Series A (296)
Series B (219)
Service/supplier (10)
Sickle cell disease (120)
Special edition (30)
Spinal muscular atrophy (168)
Sponsored (53)
Startups (3510)
State (1)
Stomach cancer (21)
Supply chain (136)
Tariffs (104)
The Weekly (128)
Vaccines (1245)
Venture capital (128)
Weight loss (588)
Women's health (124)
Worklife (24)
Date
Today (134)
Last 7 days (642)
Last 30 days (3104)
Last 365 days (30437)
2026 (14659)
2025 (30370)
2024 (34506)
2023 (38792)
2022 (49835)
2021 (54034)
2020 (52315)
2019 (44307)
2018 (33657)
2017 (32114)
2016 (31046)
2015 (34975)
2014 (28101)
2013 (23387)
2012 (25189)
2011 (25528)
2010 (23797)
Location
Africa (823)
Alabama (88)
Alaska (6)
Arizona (332)
Arkansas (15)
Asia (41105)
Australia (6862)
California (13340)
Canada (3457)
China (1466)
Colorado (556)
Connecticut (599)
Delaware (409)
Europe (93675)
Florida (2040)
Georgia (442)
Hawaii (4)
Idaho (58)
Illinois (1124)
India (87)
Indiana (577)
Iowa (23)
Japan (573)
Kansas (124)
Kentucky (50)
Louisiana (53)
Maine (81)
Maryland (1616)
Massachusetts (9675)
Michigan (344)
Minnesota (721)
Mississippi (7)
Missouri (154)
Montana (25)
Nebraska (26)
Nevada (142)
New Hampshire (86)
New Jersey (3572)
New Mexico (22)
New York (3488)
North Carolina (1732)
North Dakota (10)
Northern California (6756)
Ohio (395)
Oklahoma (23)
Oregon (40)
Pennsylvania (2595)
Puerto Rico (24)
Rhode Island (45)
South America (1196)
South Carolina (85)
South Dakota (2)
Southern California (5289)
Tennessee (211)
Texas (2150)
United States (47303)
Utah (368)
Vermont (1)
Virginia (337)
Washington D.C. (82)
Washington State (1074)
West Virginia (4)
Wisconsin (140)
Wyoming (2)
680,677 Results for "morpheus medical s l".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
The real potential of PD-(L)1×VEGF bispecifics may be outside lung cancer
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.
May 28, 2026
·
6 min read
·
Souro Chowdhury
Press Releases
Anaergia S.r.l. Expands Scope at Three Biomethane Facilities Being Built for QGM S.á.r.l. in Italy, Increasing Contracts by C$17 Million
March 17, 2026
·
3 min read
Press Releases
Phiusion Labs Inc. Announces Strategic Distribution Partnership with Proteos Biotech S.L. for PBSerum® in the United States and Canada
April 13, 2026
·
2 min read
Press Releases
Disclosure of a transparency notification from AOC Pharma S.à r.l.
March 1, 2026
·
2 min read
Press Releases
OliX Pharmaceuticals Secures KRW 110 Billion Investment from BOLD, L’Oréal Corporate Venture Capital Fund, and Weiss, U.S. Hedge Fund
June 4, 2026
·
3 min read
Cancer
ASCO’s biggest winners showcased a new era of cancer innovation
Revolution Medicines stole the show at the 2026 American Society of Clinical Oncology meeting as full data from its pancreatic cancer drug lived up to expectations, while Summit and Akeso proved the PD-(L)1/VEGF mechanism and Eli Lilly showed that its in vivo CAR T bet is paying off.
June 3, 2026
·
7 min read
·
Heather McKenzie
Press Releases
L7 Informatics Announces L7 SYNAPSE™: Advancing Context-Aware AI for Regulated Scientific Execution
April 9, 2026
·
1 min read
Press Releases
Digital Disruption in Life Sciences: L7 Informatics Says Competitive Advantage Will Come From Governed Execution
L7 Informatics CEO explains why the next wave of life sciences innovation depends on digital unified platforms that orchestrate workflows, contextualize data, and enable AI-actionable operations.
February 12, 2026
·
1 min read
Pipeline
Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer
Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns.
April 24, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Predicta Biosciences Appoints Dr. Craig L. Tendler as Independent Director to its Board
May 20, 2026
·
2 min read
1 of 68,068
Next
